1. 方法論と範囲
1.1. 調査方法
1.2. 調査目的と調査範囲
2. 定義と概要
3. エグゼクティブ・サマリー
3.1. 治療タイプ別スニペット
3.2. 治療領域別スニペット
3.3. 投与形態別スニペット
3.4. エンドユーザー別
3.5. 地域別スニペット
4. ダイナミクス
4.1. 影響要因
4.1.1. 推進要因
4.1.1.1. 新しい遺伝子治療を開発するための主要市場プレイヤー間の協力の増加
4.1.1.2. 癌の有病率の上昇
4.1.2. 阻害要因
4.1.2.1. 細胞＆遺伝子治療に伴う課題
4.1.2.2. XX
4.1.3. 機会
4.1.4. 影響分析
5. 産業分析
5.1. ポーターのファイブフォース分析
5.2. サプライチェーン分析
5.3. 価格分析
5.4. 規制分析
5.5. 特許分析
5.6. PESTLE分析
5.7. SWOT分析
5.8. DMI意見
6. 治療タイプ別
6.1. はじめに
6.1.1. 市場規模分析および前年比成長率分析（%）（治療タイプ別
6.1.2. 市場魅力度指数（治療タイプ別
6.2. 細胞療法
6.2.1. 序論
6.3. 遺伝子治療
7. 治療領域別
7.1. はじめに
7.1.1. 市場規模分析および前年比成長率分析(%), 治療領域別
7.1.2. 市場魅力度指数、治療領域別
7.2. オンコロジー（がん）*市場
7.2.1. 序論
7.2.2. 市場規模分析と前年比成長率分析(%)
7.3. 希少疾患
7.4. 心血管疾患
7.5. 神経疾患
7.6. 眼科
7.7. 整形外科疾患
7.8. 血液疾患
7.9. その他
8. 投与形態別
8.1. 導入
8.1.1. 市場規模分析および前年比成長率分析（%）, 配達モード別
8.1.2. 市場魅力度指数（デリバリーモード別
8.2. インビボ*市場
8.2.1. はじめに
8.2.2. 市場規模分析と前年比成長率分析(%)
8.3. 生体外
9. エンドユーザー別
9.1. はじめに
9.1.1. 市場規模分析および前年比成長率分析(%), エンドユーザー別
9.1.2. 市場魅力度指数、エンドユーザー別
9.2. 病院・クリニック*市場
9.2.1. はじめに
9.2.2. 市場規模分析と前年比成長率分析(%)
9.3. 研究機関
9.4. バイオ医薬品企業
9.5. 学術機関
10. 地域別
10.1. はじめに
10.1.1. 地域別市場規模分析および前年比成長率分析(%)
10.1.2. 市場魅力度指数、地域別
10.2. 北米
10.2.1. 序論
10.2.2. 主な地域別ダイナミクス
10.2.3. 市場規模分析および前年比成長率分析（%）（治療タイプ別
10.2.4. 市場規模分析およびYoY成長率分析（%）、治療領域別
10.2.5. 市場規模分析および前年比成長率分析（%）, 投与形態別
10.2.6. 市場規模分析および前年比成長率分析（%）, エンドユーザー別
10.2.7. 市場規模分析および前年比成長率分析（%）, 国別
10.2.7.1. 米国
10.2.7.2. カナダ
10.2.7.3. メキシコ
10.3. ヨーロッパ
10.3.1. はじめに
10.3.2. 主な地域別ダイナミクス
10.3.3. 市場規模分析および前年比成長率分析（%）（治療タイプ別
10.3.4. 市場規模分析およびYoY成長率分析（%）、治療領域別
10.3.5. 市場規模分析およびYoY成長分析(%)、送達モード別
10.3.6. 市場規模分析および前年比成長率分析（%）, エンドユーザー別
10.3.7. 市場規模分析および前年比成長率分析（%）, 国別
10.3.7.1. ドイツ
10.3.7.2. イギリス
10.3.7.3. フランス
10.3.7.4. イタリア
10.3.7.5. スペイン
10.3.7.6. その他のヨーロッパ
10.4. 南米
10.4.1. はじめに
10.4.2. 地域別主要市場
10.4.3. 市場規模分析および前年比成長率分析（%）（治療タイプ別
10.4.4. 市場規模分析およびYoY成長率分析（%）、治療領域別
10.4.5. 市場規模分析およびYoY成長分析(%)、送達モード別
10.4.6. 市場規模分析および前年比成長率分析（%）, エンドユーザー別
10.4.7. 市場規模分析および前年比成長率分析（%）, 国別
10.4.7.1. ブラジル
10.4.7.2. アルゼンチン
10.4.7.3. その他の南米諸国
10.5. アジア太平洋
10.5.1. 序論
10.5.2. 主な地域別ダイナミクス
10.5.3. 市場規模分析および前年比成長率分析（%）（治療タイプ別
10.5.4. 市場規模分析およびYoY成長率分析（%）、治療領域別
10.5.5. 市場規模分析および前年比成長率分析（%）、送達モード別
10.5.6. 市場規模分析および前年比成長率分析（%）, エンドユーザー別
10.5.7. 市場規模分析および前年比成長率分析（%）, 国別
10.5.7.1. 中国
10.5.7.2. インド
10.5.7.3. 日本
10.5.7.4. 韓国
10.5.7.5. その他のアジア太平洋地域
10.6. 中東・アフリカ
10.6.1. 序論
10.6.2. 主な地域別ダイナミクス
10.6.3. 市場規模分析および前年比成長率分析（%）（治療タイプ別
10.6.4. 市場規模分析およびYoY成長率分析（%）、治療領域別
10.6.5. 市場規模分析および前年比成長率分析 (%)、送達モード別
10.6.6. 市場規模分析および前年比成長率分析（%）, エンドユーザー別
11. 競合情勢
11.1. 競争シナリオ
11.2. 市場ポジショニング／シェア分析
11.3. M&A分析
12. 企業プロフィール
12.1. Novartis*
12.1.1. 会社概要
12.1.2. 製品ポートフォリオと内容
12.1.3. 財務概要
12.1.4. 主な展開
12.2. Gilead Sciences (Kite Pharma)
12.3. Bristol-Myers Squibb
12.4. Bluebird Bio
12.5. Spark Therapeutics (Roche)
12.6. Sarepta Therapeutics
12.7. UniQure
12.8. Biomarin Pharmaceutical
12.9. Fate Therapeutics
12.10. Cellectis
リストは網羅的ではありません
13. 付録
13.1. 会社概要とサービス
13.2. お問い合わせ
Global Cell and Gene Therapy Market reached US$ 16.5 billion in 2023 and is expected to reach US$ 70.1 billion by 2031, growing at a CAGR of 18.6% during the forecast period 2024-2031.
Cell therapy involves transferring live cells to a patient to treat or prevent diseases. These cells can be autologous or allogeneic, and can transform into different cell types. Pluripotent cells can transform into any cell type, while multipotent cells have a more limited repertoire. Differentiated or primary cells are fixed types, and the type of cells administered depends on the treatment.
Gene therapy is the use of genetic material to treat or prevent diseases by altering the production of a single or group of proteins in cells. It can reduce disease-causing protein levels, increase disease-fighting protein production, or produce new or modified proteins.
Market Dynamics: Drivers & Restraints
Increasing collaboration between the key market players to develop new gene therapies
The cell and gene therapy market is growing due to strategic alliances among biotechnology firms, pharmaceutical companies, and academic institutions. These partnerships enable sharing of expertise, technology, and resources, facilitating faster clinical trials and regulatory approvals. They also help companies address complex genetic disorders more effectively and expand their pipelines.
For instance, on February 15, 2023, Charles River Laboratories International, Inc., a pharmaceutical company, and Purespring Therapeutics, a pioneering gene therapy company focused on transforming the treatment of kidney diseases, announced a plasmid DNA contract development and manufacturing organization (CDMO) collaboration. Under the collaboration, the gene therapy platform targeting renal diseases, using Charles River's established plasmid platform, eXpDNA, and decades of experience at the company's plasmid DNA manufacturing center of excellence.
Challenges associated with the cell and gene therapy
The development of CAR T-cell therapies faces challenges such as safety and efficacy issues, clinical study protocols, strict regulatory frameworks, and high costs. Key elements include treating heterogeneous systems with various cells, high gene transfer efficiency, low cell toxicity, and single cell specificity.
However, one in five cancer patients who qualify for these therapies die waiting for production facilities. Despite these challenges, some autologous products can now be produced in less than two weeks. The health sector is exploring the development of more sophisticated gene-transfer tools with CARs and centralized organization with standardized apheresis centers, such as collection and reinfusion.
Segment Analysis
The global cell and gene therapy market is segmented based on therapy type, therapeutic area, mode of delivery, end user and region.
The cell therapy from the therapy type segment accounted for approximately 54.3% of the cell and gene therapy market share
The cell therapy from the therapy type segment accounted for approximately 54.3%. implants are vital for osseointegration, a process where the implant acts as an artificial tooth root. Cell therapy is a key player in the cell and gene therapy market, offering transformative treatments for diseases like cancer, autoimmune disorders, and genetic conditions.
Cell-based therapies like CAR-T cells and stem cell therapies repair, replace, or regenerate damaged tissues and organs. The success of CAR-T cell therapies in treating cancer has increased interest and investment in the field. As clinical trials show positive outcomes, cell therapy is seen as a vital component of precision medicine, driving personalized healthcare advancements and expanding market applications.
For instance, in August 2024, the Food and Drug Administration (FDA) approved a cellular therapy called afamitresgene autoleucel, or afami-cel (Tecelra), to treat some people with metastatic synovial sarcoma, a type of soft tissue sarcoma. The decision marks the first time the agency has approved a treatment called a T-cell receptor (TCR) therapy for cancer.
Geographical Analysis
North America is estimated to hold about 38.4% of the total market share throughout the forecast period
North America is estimated to hold about 38.4% of the total market share throughout the forecast period due to rise in the prevalence of cancers, FDA approvals, highest number of gene therapy clinical trials, with over 400 enterprises actively developing cell and gene therapy products for various disorders.
For instance, in April 2024, Walgreens proposed to collaborate with drugmakers to offer cell and gene therapies to US patients as part of its expansion of specialty pharmacy services. The company will open a licensed facility in Pittsburgh for these services, as specialty pharmacies play a crucial role in the US health system, particularly in the fight against chronic diseases.
Market Segmentation
By Therapy Type
• Cell Therapy
• Gene Therapy
By Therapeutic Area
• Oncology (Cancer)
• Rare Diseases
• Cardiovascular Diseases
• Neurological Disorders
• Ophthalmology
• Orthopedic Diseases
• Hematological Disorders
• Others
By Mode of Delivery
• In Vivo
• Ex Vivo
By End-User
• Hospitals & Clinics
• Research Institutes
• Biopharmaceutical Companies
• Academic Institutions
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o UK
o France
o Italy
o Spain
o Rest of Europe
• South America
o Brazil
o Argentina
o Rest of South America
• Asia-Pacific
o China
o India
o Japan
o South Korea
o Rest of Asia-Pacific
• Middle East and Africa
Competitive Landscape
The major global players in the market include Novartis, Gilead Sciences (Kite Pharma), Bristol-Myers Squibb, Bluebird Bio, Spark Therapeutics (Roche), Sarepta Therapeutics, UniQure, Biomarin Pharmaceutical, Fate Therapeutics, Cellectis among others.
Key Developments
In April 2024, India has launched its first indigenous CAR T-cell therapy, NexCAR19, for cancer treatment. The therapy, developed by IIT Bombay and the Tata Memorial Centre, is a "major breakthrough" that offers a new hope for the fight against the disease. The therapy, which is the first "Made in India" CAR T-cell therapy, will help cure various types of cancer and significantly reduce the cost of cancer treatment. The launch event took place at the Indian Institute of Technology (IIT) Bombay in Mumbai.
In August 2024, Precigen, Inc., a biopharmaceutical company, has announced a strategic reprioritization of its clinical portfolio and resource streamlining, including a 20% workforce reduction, to focus on commercializing the PRGN-2012 AdenoVerse gene therapy for recurrent respiratory papillomatosis, a treatment that could improve patient lives.
Why Purchase the Report?
• To visualize the global cell and gene therapy
Market Segmentation based on therapy type, therapeutic area, mode of delivery, end user and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of the cell and gene therapy market level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The global cell and gene therapy market report would provide approximately 64 tables, 61 figures and 186 pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies
1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Therapy Type
3.2. Snippet by Therapeutic Area
3.3. Snippet by Mode of Delivery
3.4. Snippet by End User
3.5. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Increasing collaboration between the key market players to develop new gene therapies
4.1.1.2. Rise in the prevalence of cancers
4.1.2. Restraints
4.1.2.1. Challenges associated with the cell and gene therapy
4.1.2.2. XX
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Patent Analysis
5.6. PESTLE Analysis
5.7. SWOT Analysis
5.8. DMI Opinion
6. By Therapy Type
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
6.1.2. Market Attractiveness Index, By Therapy Type
6.2. Cell Therapy*
6.2.1. Introduction
6.3. Gene Therapy
7. By Therapeutic Area
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Area
7.1.2. Market Attractiveness Index, By Therapeutic Area
7.2. Oncology (Cancer)*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Rare Diseases
7.4. Cardiovascular Diseases
7.5. Neurological Disorders
7.6. Ophthalmology
7.7. Orthopedic Diseases
7.8. Hematological Disorders
7.9. Others
8. By Mode of Delivery
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Mode of Delivery
8.1.2. Market Attractiveness Index, By Mode of Delivery
8.2. In Vivo*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Ex Vivo
9. By End User
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
9.1.2. Market Attractiveness Index, By End User
9.2. Hospitals & Clinics*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Research Institutes
9.4. Biopharmaceutical Companies
9.5. Academic Institutions
10. By Region
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Area
10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Mode of Delivery
10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.2.7.1. U.S.
10.2.7.2. Canada
10.2.7.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Area
10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Mode of Delivery
10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.3.7.1. Germany
10.3.7.2. UK
10.3.7.3. France
10.3.7.4. Italy
10.3.7.5. Spain
10.3.7.6. Rest of Europe
10.4. South America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Area
10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Mode of Delivery
10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.4.7.1. Brazil
10.4.7.2. Argentina
10.4.7.3. Rest of South America
10.5. Asia-Pacific
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Area
10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Mode of Delivery
10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.5.7.1. China
10.5.7.2. India
10.5.7.3. Japan
10.5.7.4. South Korea
10.5.7.5. Rest of Asia-Pacific
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Area
10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Mode of Delivery
10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
11. Competitive Landscape
11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis
12. Company Profiles
12.1. Novartis*
12.1.1. Company Overview
12.1.2. Product Portfolio and Description
12.1.3. Financial Overview
12.1.4. Key Developments
12.2. Gilead Sciences (Kite Pharma)
12.3. Bristol-Myers Squibb
12.4. Bluebird Bio
12.5. Spark Therapeutics (Roche)
12.6. Sarepta Therapeutics
12.7. UniQure
12.8. Biomarin Pharmaceutical
12.9. Fate Therapeutics
12.10. Cellectis
LIST NOT EXHAUSTIVE
13. Appendix
13.1. About Us and Services
13.2. Contact Us
❖ 世界の細胞＆遺伝子治療市場に関するよくある質問(FAQ) ❖
・細胞＆遺伝子治療の世界市場規模は？
→DataM Intelligence社は2023年の細胞＆遺伝子治療の世界市場規模を165億米ドルと推定しています。
・細胞＆遺伝子治療の世界市場予測は？
→DataM Intelligence社は2031年の細胞＆遺伝子治療の世界市場規模を701億米ドルと予測しています。
・細胞＆遺伝子治療市場の成長率は？
→DataM Intelligence社は細胞＆遺伝子治療の世界市場が2024年～2031年に年平均18.6%成長すると予測しています。
・世界の細胞＆遺伝子治療市場における主要企業は？
→DataM Intelligence社は「Novartis, Gilead Sciences (Kite Pharma), Bristol-Myers Squibb, Bluebird Bio, Spark Therapeutics (Roche), Sarepta Therapeutics, UniQure, Biomarin Pharmaceutical, Fate Therapeutics, Cellectisなど ...」をグローバル細胞＆遺伝子治療市場の主要企業として認識しています。
※上記FAQの市場規模、市場予測、成長率、主要企業に関する情報は本レポートの概要を作成した時点での情報であり、納品レポートの情報と少し異なる場合があります。
